OXBDF (OXBDF) Stock Price & Analysis
OXBDF (OXBDF) rose 1.69% to USD 8.44 as of June 10, 2026 at 02:24 UTC, according to Nexqual real-time market data.
OXBDF last closed at USD 8.3; the session ranged USD 8.44–8.45 on volume of 16,300 shares. Market capitalization is $1.02B, with a 52-week range of USD 4.23–12.61 (PNK). Source: Nexqual, June 10, 2026 at 02:24 UTC.
Key Statistics (as of June 10, 2026 at 02:24 UTC)
| Price | USD 8.44 |
|---|---|
| Change | ▲ 1.69% (up) |
| Previous Close | USD 8.3 |
| Open | USD 8.45 |
| Day Range | USD 8.44 – 8.45 |
| 52-Week Range | USD 4.23 – 12.61 |
| Volume | 16,300 shares |
| Market Cap | $1.02B |
| Exchange | PNK |
Technical Analysis (OXBDF)
Nexqual's technical model rates OXBDF "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 02:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.67 (neutral) |
| vs SMA50 | Above (USD 8.12) |
| MACD | -0.07 (negative) |
Analyst Ratings (OXBDF)
Wall Street analysts rate OXBDF "None", per Nexqual as of June 10, 2026 at 02:24 UTC.
| Consensus Rating | None |
|---|
Earnings (OXBDF)
| Next Earnings Date | 2026-03-26 |
|---|
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Financials & Fundamentals (OXBDF)
| Total Revenue | $168.74M |
|---|---|
| Revenue Growth (YoY) | +22.50% |
| Gross Margin | +39.10% |
| Operating Margin | -7.88% |
| Profit Margin | -17.85% |
| ROE | -40.37% |
| Debt / Equity | 162.16 |
| Current Ratio | 2.2 |
| Total Cash | $96.90M |
| Total Debt | $148.13M |
| Free Cash Flow | $-13,250 |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Financial Health Score (OXBDF)
Nexqual rates OXBDF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:24 UTC.
| Growth | Strong — Revenue +31% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 39%, operating -8% |
| Balance Sheet | Weak — $97M cash vs $148M debt |
| Cash Flow | Weak — FCF negative: -$13K, burning cash |
| Efficiency | Critical — ROE -40%, ROA -7.0% |
Ownership (OXBDF)
| Insider Ownership | +20.66% |
|---|---|
| Institutional Ownership | +55.22% |
| Shares Outstanding | 121.01M |
| Float | 60.81M |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Leadership (OXBDF)
OXBDF is led by Frank Mathias (age 63), CEO & Director, per Nexqual as of June 10, 2026 at 02:24 UTC.
| CEO & Director | Frank Mathias (age 63) |
|---|---|
| CFO & Director | Lucinda Clair Crabtree (age 46) |
Major Backers & Investors (OXBDF)
Notable institutional backers of OXBDF include abrdn World Healthcare Fund, according to Nexqual as of June 10, 2026 at 02:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| abrdn World Healthcare Fund | 1.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.3% |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHGUF | Pharming Group NV | USD 1.18 | ▲ 0% |
| CLVLY | Clinuvel Pharmaceuticals Ltd. | USD 6.36 | ▼ 3.64% |
| INRLF | Valneva SE | USD 2.8 | ▲ 2.19% |
| PTCHF | PureTech Health PLC | USD 1.8 | ▼ 3.33% |
| CLVLF | Clinuvel Pharmaceuticals Ltd. | USD 6.4 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:24 UTC. This page is informational and not investment advice.